Abstract
The global therapeutic botulinum toxin (BTX) market, including the US, Europe
(France, Germany, Italy, Spain, and the UK), and Japan, exceeded $600 million
in 2008
Through 2013, growth will be fueled by the approval of new treatment
indications of BTX, which will significantly expand procedure volumes and
bolster unit demand
Table of Contents
TABLE OF CONTENTS
LIST OF EXHIBITS
EXECUTIVE SUMMARY
METHODOLOGY
1.0 GLOBAL THERAPEUTIC BOTULINUM TOXIN MARKET
- 1.1 Market Overview
- 1.2 Market Analysis
- 1.2.1 Product Background
- 1.2.2 Procedure Overview
- 1.2.2.1 US Procedures
- Cervical Dystonia Procedures
- Blepharospasm Procedures
- Strabismus Procedures
- Severe Primary Axillary Hyperhidrosis
- 1.2.2.2 European Procedures
- 1.2.2.3 Japanese Procedures
- 1.2.2.4 Emerging Procedures
- 1.2.3 Market Forecast
- 1.2.3.1 US Therapeutic Botulinum Toxin Market
- 1.2.3.2 European Therapeutic Botulinum Toxin Market
- 1.2.3.3 Japanese Therapeutic Botulinum Toxin Market
- 1.2.4 Market Drivers and Limiters
- 1.2.4.1 Market Drivers
- 1.2.4.2 Market Limiters
- 1.3 Competitive Analysis
- 1.3.1 Leading Competitors
- 1.3.2 Emerging Competitors
2.0 US THERAPEUTIC BOTULINUM TOXIN MARKET
- 2.1 Market Overview
- 2.2 Market Analysis
- 2.2.1 Market Forecast
- 2.2.2 Market Drivers and Limiters
- 2.2.2.1 Market Drivers
- 2.2.2.2 Market Limiters
- 2.3 Competitive Analysis
- 2.3.1 Leading Competitors
- 2.3.2 Emerging Competitors
3.0 EUROPEAN THERAPEUTIC BOTULINUM TOXIN MARKET
- 3.1 Market Overview
- 3.2 Market Analysis
- 3.2.1 Market Forecast
- 3.2.2 Market Drivers and Limiters
- 3.2.2.1 Market Drivers
- 3.2.2.2 Market Limiters
- 3.3 Competitive Analysis
- 3.3.1 Leading Competitors
- 3.3.2 Emerging Competitors
4.0 JAPANESE THERAPEUTIC BOTULINUM TOXIN MARKET
- 4.1 Market Overview
- 4.2 Market Analysis
- 4.2.1 Market Forecast
- 4.2.2 Market Drivers and Limiters
- 4.2.2.1 Market Drivers
- 4.2.2.2 Market Limiters
- 4.3 Competitive Analysis
- 4.3.1 Leading Competitors
- 4.3.2 Emerging Competitors
APPENDIX A: MRG ACRONYMS AND INITIALISMS
APPENDIX B: SUPPLEMENTAL EXHIBITS
List of Exhibits
- EXECUTIVE SUMMARY
- Exhibit 1: Therapeutic BTX Market, Global (US$), 2007 - 2013
- Exhibit 2: Therapeutic BTX Market, by Indication, US, as a % of Total,
2008 and 2013
- Exhibit 3: Therapeutic BTX Market Units, Europe, 2007 - 2013
- Exhibit 4: Therapeutic BTX Market, Japan (US$), 2007 - 2013
- Exhibit 5: Leading Competitors in the Therapeutic BTX Market, Global, 2008
METHODOLOGY
- Exhibit 6: Currency Exchange Rates, 2008
CHAPTER 1: GLOBAL THERAPEUTIC BOTULINUM TOXIN MARKET
- Exhibit 7: Therapeutic BTX Market, by Country, Global (US$), 2007 - 2013
(Graphical Format)
- Exhibit 8: Therapeutic BTX Product Overview, Global, 2008
- Exhibit 9: Therapeutic BTX Procedures, by Country, Global, 2007 - 2013
- Exhibit 10: Therapeutic BTX Procedures, by Procedure Type, US, 2007 - 2013
- Exhibit 11: Therapeutic BTX Procedures, by Country, Europe, 2007 - 2013
- Exhibit 12: Therapeutic BTX Procedures, Japan, 2007 - 2013
- Exhibit 13: Therapeutic BTX Market, by Country, Global (US$), 2007 - 2013
(Tabular Format)
- Exhibit 14: Therapeutic BTX Market, by Country, Global (€ , £,
and ¥), 2007 - 2013 Exhibit 15: Drivers and Limiters of the Therapeutic BTX
Market, Global
- Exhibit 16: Leading Competitors in the Therapeutic BTX Market, by Country,
as % of Total, Global, 2008
CHAPTER 2: US THERAPEUTIC BOTULINUM TOXIN MARKET
- Exhibit 17: Therapeutic BTX Market, US (US$), 2007 - 2013 (Graphical
Format)
- Exhibit 18: Therapeutic BTX Market, US (US$), 2007 - 2013 (Tabular Format)
- Exhibit 19: Therapeutic BTX Market Growth, US, 2008 - 2013
- Exhibit 20: Drivers and Limiters of the Therapeutic BTX Market, US
- Exhibit 21: Leading Competitors in the Therapeutic BTX Market, as a % of
Total, US, 2008
CHAPTER 3: EUROPEAN THERAPEUTIC BOTULINUM TOXIN MARKET
- Exhibit 22: Therapeutic BTX Market, by Country, Europe (US$), 2007 - 2013
(Graphical Format)
- Exhibit 23: Therapeutic BTX Market, by Country, Europe (US$), 2007 - 2013
(Tabular Format)
- Exhibit 24: Therapeutic BTX Market, by Country, Europe (€ and
£), 2007 - 2013
- Exhibit 25: Therapeutic BTX Market Growth, by Country, Europe, 2008 - 2013
- Exhibit 26: Drivers and Limiters of the Therapeutic BTX Market, Europe
- Exhibit 27: Leading Competitors in the Therapeutic BTX Market, by Country,
as a % of Total, Europe, 2008
CHAPTER 4: JAPANESE THERAPEUTIC BOTULINUM TOXIN MARKET
- Exhibit 28: Therapeutic BTX Market, Japan (US$), 2007 - 2013
- Exhibit 29: Therapeutic BTX Market, Japan (US$ and ¥), 2007 - 2013
- Exhibit 30: Therapeutic BTX Market Growth, Japan, 2008 - 2013
- Exhibit 31: Drivers and Limiters of the Therapeutic BTX Market, Japan
- Exhibit 32: Leading Competitors in the Therapeutic BTX Market, as a % of
Total, Japan, 2008
APPENDIX B: SUPPLEMENTAL EXHIBITS
- Exhibit 33: Therapeutic BTX Market, Global (US$), 2007 - 2013 (Detailed
Format)
- Exhibit 34: Therapeutic BTX Market, by Indication, US, as a % of Total,
2008 and 2013 (Detailed Format)
- Exhibit 35: Therapeutic BTX Market Units, Europe, 2007 - 2013 (Detailed
Format)
- Exhibit 36: Therapeutic BTX Market, Japan (US$), 2007 - 2013 (Detailed
Format)
|
有關報告
|
